Literature DB >> 15985649

HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services.

Don C Des Jarlais1, Theresa Perlis, Kamyar Arasteh, Lucia V Torian, Sara Beatrice, Judith Milliken, Donna Mildvan, Stanley Yancovitz, Samuel R Friedman.   

Abstract

OBJECTIVES: We sought to estimate HIV incidence among injection drug users (IDUs) in New York City from 1990 to 2002 to assess the impact of an expansion of syringe exchange services. Syringe exchange increased greatly during this period, from 250,000 to 3,000,000 syringes exchanged annually.
METHODS: Serum samples were obtained from serial cross-sectional surveys of 3,651 IDUs. HIV-positive samples were tested with the Serologic Test Algorithm for Recent HIV Seroconversion (STARHS) assay to identify recent HIV infections and to estimate HIV incidence. Consistency with other incidence studies was used to assess strengths and limitations of STARHS.
RESULTS: HIV incidence declined from 3.55/100 person-years at risk (PYAR) from 1990-1992, to 2.63/100 PYAR from 1993-1995, to 1.05/100 PYAR from 1996-1998, and to 0.77/100 PYAR from 1999-2002 (P<.001). There was a very strong negative linear relationship (r= -.99, P<.005) between the annual numbers of syringes exchanged and estimated HIV incidence. These results were highly consistent with a large number of shorter incidence studies among IDUs conducted during the time period.
CONCLUSIONS: STARHS testing of samples from large serial cross-sectional surveys can provide important data for the assessment of community-level HIV prevention.

Entities:  

Mesh:

Year:  2005        PMID: 15985649      PMCID: PMC1449378          DOI: 10.2105/AJPH.2003.036517

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  16 in total

1.  Development of AIDS, HIV seroconversion, and potential co-factors for T4 cell loss in a cohort of intravenous drug users.

Authors:  D C Des Jarlais; S R Friedman; M Marmor; H Cohen; D Mildvan; S Yancovitz; U Mathur; W el-Sadr; T J Spira; J Garber
Journal:  AIDS       Date:  1987-07       Impact factor: 4.177

2.  HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987.

Authors:  D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky
Journal:  JAMA       Date:  1989-02-17       Impact factor: 56.272

3.  Quantitative detection of increasing HIV type 1 antibodies after seroconversion: a simple assay for detecting recent HIV infection and estimating incidence.

Authors:  Bharat S Parekh; M Susan Kennedy; Trudy Dobbs; Chou-Pong Pau; Robert Byers; Timothy Green; Dale J Hu; Suphak Vanichseni; Nancy L Young; Kachit Choopanya; Timothy D Mastro; J Steven McDougal
Journal:  AIDS Res Hum Retroviruses       Date:  2002-03-01       Impact factor: 2.205

4.  Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco.

Authors:  W McFarland; M P Busch; T A Kellogg; B D Rawal; G A Satten; M H Katz; J Dilley; R S Janssen
Journal:  J Acquir Immune Defic Syndr       Date:  1999-12-15       Impact factor: 3.731

5.  Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City.

Authors:  Don C Des Jarlais; Theresa Diaz; Theresa Perlis; David Vlahov; Carey Maslow; Mary Latka; Russell Rockwell; Vincent Edwards; Samuel R Friedman; Edgar Monterroso; Ian Williams; Richard S Garfein
Journal:  Am J Epidemiol       Date:  2003-03-01       Impact factor: 4.897

6.  HIV incidence among injecting drug users in New York City syringe-exchange programmes.

Authors:  D C Des Jarlais; M Marmor; D Paone; S Titus; Q Shi; T Perlis; B Jose; S R Friedman
Journal:  Lancet       Date:  1996-10-12       Impact factor: 79.321

7.  "Informed altruism" and "partner restriction" in the reduction of HIV infection in injecting drug users entering detoxification treatment in New York City, 1990-2001.

Authors:  Don C Des Jarlais; Theresa Perlis; Kamyar Arasteh; Holly Hagan; Judith Milliken; Naomi Braine; Stanley Yancovitz; Donna Mildvan; David C Perlman; Carey Maslow; Samuel R Friedman
Journal:  J Acquir Immune Defic Syndr       Date:  2004-02-01       Impact factor: 3.731

Review 8.  The estimated prevalence and incidence of HIV in 96 large US metropolitan areas.

Authors:  S D Holmberg
Journal:  Am J Public Health       Date:  1996-05       Impact factor: 9.308

9.  Trends in human immunodeficiency virus seroincidence among street-recruited injection drug users in San Francisco, 1987-1998.

Authors:  Alex H Kral; Jennifer Lorvick; Lauren Gee; Peter Bacchetti; Bhupat Rawal; Michael Busch; Brian R Edlin
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

10.  Risk factors for human immunodeficiency virus seroconversion among out-of-treatment drug injectors in high and low seroprevalence cities. The National AIDS Research Consortium.

Authors:  S R Friedman; B Jose; S Deren; D C Des Jarlais; A Neaigus
Journal:  Am J Epidemiol       Date:  1995-10-15       Impact factor: 4.897

View more
  72 in total

1.  Assessment of HIV testing of urban injection drug users: implications for expansion of HIV testing and prevention efforts.

Authors:  Robert Heimer; Lauretta E Grau; Erin Curtin; Kaveh Khoshnood; Merrill Singer
Journal:  Am J Public Health       Date:  2006-11-30       Impact factor: 9.308

2.  The Puerto Rico-New York airbridge for drug users: description and relationship to HIV risk behaviors.

Authors:  Sherry Deren; Sung-Yeon Kang; Hector M Colón; Rafaela R Robles
Journal:  J Urban Health       Date:  2007-03       Impact factor: 3.671

Review 3.  Behavior change and health-related interventions for heterosexual risk reduction among drug users.

Authors:  Salaam Semaan; Don C Des Jarlais; Rob Malow
Journal:  Subst Use Misuse       Date:  2006       Impact factor: 2.164

4.  Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens.

Authors:  Vana Sypsa; Mina Psichogiou; Dimitrios Paraskevis; Georgios Nikolopoulos; Chrissa Tsiara; Dimitra Paraskeva; Katerina Micha; Meni Malliori; Anastasia Pharris; Lucas Wiessing; Martin Donoghoe; Samuel Friedman; Don Des Jarlais; Georgios Daikos; Angelos Hatzakis
Journal:  J Infect Dis       Date:  2017-05-15       Impact factor: 5.226

5.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

6.  Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug.

Authors:  Barbara Tempalski; Hannah L Cooper; Samuel R Friedman; Don C Des Jarlais; Joanne Brady; Karla Gostnell
Journal:  Int J Drug Policy       Date:  2008-03-04

7.  Evaluating Vancouver's supervised injection facility: data and dollars, symbols and ethics.

Authors:  Don C Des Jarlais; Kamyar Arasteh; Holly Hagan
Journal:  CMAJ       Date:  2008-11-18       Impact factor: 8.262

8.  Spatial access to sterile syringes and the odds of injecting with an unsterile syringe among injectors: a longitudinal multilevel study.

Authors:  Hannah Cooper; Don Des Jarlais; Zev Ross; Barbara Tempalski; Brian H Bossak; Samuel R Friedman
Journal:  J Urban Health       Date:  2012-08       Impact factor: 3.671

9.  The Interaction of Risk Network Structures and Virus Natural History in the Non-spreading of HIV Among People Who Inject Drugs in the Early Stages of the Epidemic.

Authors:  Kirk Dombrowski; Bilal Khan; Patrick Habecker; Holly Hagan; Samuel R Friedman; Mohamed Saad
Journal:  AIDS Behav       Date:  2017-04

10.  A national physician survey on prescribing syringes as an HIV prevention measure.

Authors:  G E Macalino; D Dhawan Sachdev; J D Rich; C Becker; L J Tan; L Beletsky; S Burris
Journal:  Subst Abuse Treat Prev Policy       Date:  2009-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.